Skip to main content
    H

    Health Catalyst Inc (HCAT)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $1.38
    -0.13 (-8.61%)

    Market Cap: $115.00M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Health Catalyst Inc (HCAT) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Health Catalyst (HCAT) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Health Catalyst reported EPS of -$0.08, below the -$0.07 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    77%(23/30)
    Avg Surprise
    +69.69%

    Upcoming Estimates

    Reports Mar 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.04
    Range-$0.05 - -$0.03
    7 analysts
    Revenue Consensus
    $51.77M
    Range$48.96M - $54.81M
    7 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS ConsensusN/A
    RangeN/A
    2 analysts
    EPS Revisions
    0
    1
    30d
    Revenue Consensus
    $49.04M
    Range$46.19M - $51.01M
    3 analysts

    Next Report

    HCAT has an expected report date of Mar 10, 2027.

    HCAT Earnings Call

    The latest HCAT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 30 quarters below that had an estimate, HCAT beat 23 and missed 7. Revenue for the quarter ended Sep 30, 2026 was $56.28M, down 26.3% from $76.32M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.08-$0.07-$0.07 - -$0.02-14.29%Miss-233.3%40 up, 3 downNov 5, 2026$56.28M
    Jun 30, 2026-$0.08-$0.05N/A-60.00%MissN/A32 up, 1 downAug 6, 2026$70.49M
    Mar 31, 2026$0.02$0.01-$0.01 - $0.05+100.00%Beat+100.0%50 up, 5 downMay 11, 2026$70.76M
    Dec 31, 2025$0.08$0.10$0.07 - $0.15-16.14%Miss+100.0%70 up, 2 downMar 12, 2026$74.68M
    Sep 30, 2025$0.06$0.07$0.04 - $0.09-14.29%Miss-14.3%81 up, 6 downNov 10, 2025$76.32M
    Jun 30, 2025-$0.08-$0.09N/A+11.11%Beat-166.7%90 up, 9 downAug 7, 2025$80.72M
    Mar 31, 2025$0.01$0.03-$0.01 - $0.04-66.67%Miss-80.0%90 up, 2 downMay 7, 2025$79.41M
    Dec 31, 2024$0.04$0.08$0.03 - $0.15-47.64%Miss+100.0%113 up, 1 downFeb 26, 2025$79.61M
    Sep 30, 2024$0.07$0.09$0.05 - $0.16-22.22%Miss+133.3%130 up, 0 downNov 6, 2024$76.35M
    Jun 30, 2024$0.12$0.08$0.05 - $0.13+50.00%Beat+140.0%130 up, 0 downAug 7, 2024$75.90M
    Mar 31, 2024$0.05$0.03-$0.06 - $0.06+66.67%Beat0.0%140 up, 0 downMay 9, 2024$74.72M
    Dec 31, 2023$0.02-$0.01-$0.11 - $0.02+300.00%BeatN/A131 up, 0 downFeb 22, 2024$75.08M
    Sep 30, 2023$0.03-$0.01-$0.13 - $0.05+400.00%BeatN/A120 up, 0 downNov 2, 2023$73.77M
    Jun 30, 2023$0.05-$0.01-$0.12 - $0.12+600.00%BeatN/A140 up, 0 downAug 8, 2023$73.21M
    Mar 31, 2023$0.05-$0.04-$0.12 - $0.02+225.00%BeatN/A130 up, 0 downMay 9, 2023$73.87M
    Dec 31, 2022-$0.05-$0.11-$0.29 - $0.00+54.55%BeatN/A120 up, 0 downFeb 28, 2023$69.16M
    Sep 30, 2022-$0.13-$0.19-$0.35 - -$0.11+31.58%BeatN/A131 up, 0 downNov 8, 2022$68.35M
    Jun 30, 2022-$0.03-$0.09-$0.27 - -$0.01+66.67%BeatN/A120 up, 0 downAug 4, 2022$70.63M
    Mar 31, 2022-$0.06-$0.11-$0.30 - -$0.01+45.45%BeatN/A110 up, 0 downMay 10, 2022$68.09M
    Dec 31, 2021-$0.19-$0.21-$0.44 - -$0.07+9.52%BeatN/A13N/AMar 1, 2022$64.72M
    Sep 30, 2021-$0.18-$0.22-$0.36 - -$0.17+18.18%BeatN/A11N/ANov 9, 2021$61.74M
    Jun 30, 2021$0.00-$0.14-$0.28 - -$0.03+98.79%BeatN/A10N/AAug 5, 2021$59.63M
    Mar 31, 2021-$0.06-$0.14-$0.25 - -$0.03+57.14%BeatN/A11N/AMay 6, 2021$55.85M
    Dec 31, 2020-$0.16-$0.19-$0.27 - -$0.12+15.79%BeatN/A12N/AFeb 25, 2021$53.28M
    Sep 30, 2020-$0.21-$0.27-$0.32 - -$0.22+22.22%BeatN/A13N/ANov 10, 2020$47.19M
    Jun 30, 2020-$0.15-$0.22-$0.31 - -$0.15+31.82%BeatN/A13N/AAug 11, 2020$43.26M
    Mar 31, 2020-$0.16-$0.26-$0.31 - -$0.21+38.46%BeatN/A9N/AMay 12, 2020$45.12M
    Dec 31, 2019-$0.21-$0.29-$0.33 - -$0.21+27.59%BeatN/A7N/AFeb 27, 2020$43.50M
    Sep 30, 2019-$0.27-$0.37-$0.41 - -$0.34+27.03%BeatN/A7N/ANov 12, 2019$39.42M
    Jun 30, 2019-$0.21-$0.32-$0.32 - -$0.29+34.38%BeatN/A4N/AJul 25, 2019$73.61M
    Mar 31, 2019-$2.17N/AN/AN/AN/AN/AN/AN/AApr 10, 2019$35.21M
    Last 31 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.07, down 75.0% from the year before. It was -$2.86 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.07-75.0%
    Dec 31, 2024$0.28+86.7%
    Dec 31, 2023$0.15N/A
    Dec 31, 2022-$0.27N/A
    Dec 31, 2021-$0.43N/A
    Dec 31, 2020-$0.68N/A
    Dec 31, 2019-$2.86N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,800 words across 4 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20262,8034
    2026Q2Jun 30, 20263,1135
    2026Q1Mar 31, 20265,20511
    2025Q4Dec 31, 20255,50312
    2025Q3Sep 30, 20257,74814
    2025Q2Jun 30, 20257,71810
    2025Q1Mar 31, 20258,41316
    2024Q4Dec 31, 20249,28015

    2026Q3 Earnings Call

    Opening remarks

    Stephanie St. Clair SVP of Finance and Investor Relations Good afternoon, and welcome to Health Catalyst's earnings call for the third quarter of 2026. I am Stephanie St. Clair, Senior Vice President of Finance and Investor Relations. With me today are Simeon Kohl, our President and Chief Executive Officer, and Jason Alger, our Chief Financial Officer. A complete disclosure of our results can be found in our press release issued today and our related Form 8-K furnished to the SEC, both of which are available on the Investor Relations section of our website at ir.healthcatalyst.com. A replay of this call will be available afterwards. Today's call includes forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements about our financial outlook, expectations for the fourth quarter and full year 2026, client migrations and client retention, future growth and strategic priorities, our ability to strengthen our foundation, our ability to achieve profitable revenue growth and deliver returns to shareholders, our long-term opportunities, retention, bookings, the impact of the Vitalware divestiture, and the general anticipated performance of our business. These forward-looking statements reflect management's views as of today and should not be relied upon as representing our views as of any subsequent date. We disclaim any obligation to update any forward-looking statement or outlook. Actual results may materially differ. Please see the risk factors in our 2025 Form 10-K filed March 12, 2026, and our third quarter Form 10-Q filed today. We will also discuss non-GAAP measures. Reconciliations to the most comparable GAAP measures are in our press release. Non-GAAP financial information is presented for supplemental purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. We will provide forward-looking guidance for certain non-GAAP measures in this earnings call and are not providing forward-looking guidance for the most directly comparable GAAP guidance measures or reconciliations because some items are not within our control or cannot be reasonably forecasted. Simeon joined us as President and CEO on September 14. With that, I'll turn the call over to him.

    Simeon Kohl President and CEO Thank you, Stephanie, and good afternoon, everyone. Earlier this afternoon, we reported third quarter revenue of $56.3 million and adjusted EBITDA of $779,000, both above the high end of our guidance ranges of $55 million–$56 million and $0–$500,000, respectively. Given our performance year to date and with Project Nexus cost reductions on track, we are reaffirming our full-year revenue and adjusted EBITDA outlook. As a reminder, Project Nexus is our strategic initiative designed to fundamentally transform our operating model and deliberately reposition our business.

    Frequently Asked Questions About HCAT

    When is Health Catalyst's next earnings date?

    Health Catalyst's next earnings report is expected for Mar 10, 2027.

    Did HCAT beat earnings estimates last quarter?

    No. Health Catalyst reported EPS of -$0.08 for the quarter ended Sep 30, 2026, below the -$0.07 estimate by 14.29%.

    What EPS do analysts expect from HCAT next quarter?

    The consensus EPS estimate for Health Catalyst for the quarter ending Dec 31, 2026 is -$0.04 from 7 analysts, with estimates from -$0.05 to -$0.03.

    How often does HCAT beat earnings estimates?

    Health Catalyst beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -13.49%.